Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY

BackgroundPatients with severe, uncontrolled asthma experience frequent exacerbations and hospitalization, leading to poor health-related quality of life. In the phase 2b PATHWAY study (NCT02054130), tezepelumab reduced by up 71% improved lung function, control, life vs placebo.ObjectiveThis analysis further assessed impact on patient-reported outcomes (PROs) in PATHWAY.MethodsAdults were randomized subcutaneous (70 mg every 4 weeks, 210 or 280 2 weeks) placebo for 52 weeks. PROs using control questionnaire–6 (ACQ-6) questionnaire (standardized) patients aged 12 years older (AQLQ[S]+12). The proportions responders (defined improvements ≥0.5 ACQ-6 AQLQ(S)+12 scores) whose was well-controlled, partially-controlled, groups identified. Asthma Daily Diary used assess changes overall symptom severity.ResultsOverall, 550 randomized. Up 82% 77% tezepelumab-treated responders, respectively, compared 70% 64% placebo-treated patients, respectively. well-controlled partially-controlled higher group than group. addition, severity.ConclusionTezepelumab treatment placebo, as indicated proportion severity dose groups. These data support benefits asthma.